Australia markets closed

Esperion Therapeutics, Inc. (0IIM.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.3700-0.1000 (-4.05%)
At close: 06:03PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.89
52-week change 38.03%
S&P500 52-week change 326.49%
52-week high 33.3150
52-week low 30.7100
50-day moving average 32.5071
200-day moving average 31.6700

Share statistics

Avg vol (3-month) 326.66k
Avg vol (10-day) 36.83k
Shares outstanding 526.81M
Implied shares outstanding 6N/A
Float 8174.82M
% held by insiders 10.45%
% held by institutions 166.45%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -37.65%
Operating margin (ttm)52.47%

Management effectiveness

Return on assets (ttm)-6.94%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)229.74M
Revenue per share (ttm)1.83
Quarterly revenue growth (yoy)466.10%
Gross profit (ttm)N/A
EBITDA -34.56M
Net income avi to common (ttm)-86.51M
Diluted EPS (ttm)-6.2400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)226.61M
Total cash per share (mrq)1.2
Total debt (mrq)548.87M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.22
Book value per share (mrq)-1.57

Cash flow statement

Operating cash flow (ttm)-27.3M
Levered free cash flow (ttm)-45.36M